Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.78 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003856 | 0.88 | ACLY (1.00) | ACLYMAPK8HTR6 | |
| SCHEMBL22022202 | 0.80 | PLA2G2A (0.52) | ACLYMAPK8PLA2G2AMAPTMAPK9 | |
| SCHEMBL22022120 | 0.79 | ACLY (0.62) | ACLYMAPK8MAPTHTR6 | |
| SCHEMBL22005111 | 0.77 | MAPK8 (0.56) | ACLYMAPK8PLA2G2AMAPT | |
| SCHEMBL4711184 | 0.71 | MAPK8 (0.62) | MAPK8PLA2G2A | |
| SCHEMBL4710283 | 0.70 | MAPK8 (0.61) | MAPK8PLA2G2AMAPK9MAPK10 | |
| SCHEMBL28409032 | 0.70 | ACLY (0.57) | ACLYMAPTHTR6PTGDRPTGDR2 | |
| SCHEMBL4712288 | 0.70 | MAPK8 (0.61) | MAPK8PLA2G2AMAPK9MAPK10 | |
| SCHEMBL8687160 | 0.70 | ACLY (0.62) | ACLYMAPK8 | |
| SCHEMBL8687705 | 0.70 | KDM4E (0.53) | ACLYMAPK8MAPTMAPK9PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885MAPK8 3384/4885PLA2G2A 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.